HGEN Stock Overview
Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States.
+ 2 more risks
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.11|
|52 Week High||US$29.20|
|52 Week Low||US$5.59|
|1 Month Change||-8.94%|
|3 Month Change||-64.87%|
|1 Year Change||-35.95%|
|3 Year Change||88.00%|
|5 Year Change||-67.84%|
|Change since IPO||-98.09%|
Recent News & Updates
Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|HGEN||US Biotechs||US Market|
Return vs Industry: HGEN underperformed the US Biotechs industry which returned 5.3% over the past year.
Return vs Market: HGEN underperformed the US Market which returned 21.3% over the past year.
|HGEN Average Weekly Movement||16.5%|
|Biotechs Industry Average Movement||8.6%|
|Market Average Movement||5.9%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.2%|
Stable Share Price: HGEN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: HGEN's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company’s lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders.
Humanigen Fundamentals Summary
|HGEN fundamental statistics|
Is HGEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HGEN income statement (TTM)|
|Cost of Revenue||US$139.54m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-3.69|
|Net Profit Margin||-8,202.23%|
How did HGEN perform over the long term?See historical performance and comparison
Is Humanigen undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HGEN ($6.11) is trading below our estimate of fair value ($305.61)
Significantly Below Fair Value: HGEN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: HGEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HGEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HGEN has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
How is Humanigen forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HGEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HGEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HGEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HGEN's revenue (48.9% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: HGEN's revenue (48.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HGEN's Return on Equity is forecast to be very high in 3 years time (125.5%).
How has Humanigen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HGEN is currently unprofitable.
Growing Profit Margin: HGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HGEN is unprofitable, and losses have increased over the past 5 years at a rate of 54.8% per year.
Accelerating Growth: Unable to compare HGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: HGEN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Humanigen's financial position?
Financial Position Analysis
Short Term Liabilities: HGEN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: HGEN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: HGEN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: HGEN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HGEN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if HGEN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Humanigen current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Cameron Durrant (61 yo)
Dr. Cameron Durrant, MD, MBA, DRCOG, DIPCH, MRCGP, has been Chairman of Humanigen, Inc. since January 2016 and served as its Interim Chief Financial Officer since July 1, 2019 until July 31, 2020. Dr. Durr...
CEO Compensation Analysis
Compensation vs Market: Cameron's total compensation ($USD2.44M) is above average for companies of similar size in the US market ($USD1.70M).
Compensation vs Earnings: Cameron's compensation has increased whilst the company is unprofitable.
Experienced Management: HGEN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: HGEN's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.6%.
Humanigen, Inc.'s employee growth, exchange listings and data sources
- Name: Humanigen, Inc.
- Ticker: HGEN
- Exchange: NasdaqCM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$389.929m
- Shares outstanding: 63.82m
- Website: https://www.humanigen.com
Number of Employees
- Humanigen, Inc.
- 533 Airport Boulevard
- Suite 400
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/26 23:11|
|End of Day Share Price||2021/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.